ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,505.00
      -0.71%
      US Tech 100
      19,000.00
      -0.94%
      Dow Jones
      40,287.53
      -0.93%
      Brent Oil
      82.29
      0.01%
      Bitcoin
      68,060.17
      -0.14%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Carisma Therapeutics Inc (CARM) Quote

      Carisma Therapeutics Inc

      Carisma Therapeutics Inc (CARM)

      Carmanah Minerals Corp
      Carrefour Property Development
      1.10
      -0.04
      (-3.51%)
      Closed July 21 4:00PM
      Delayed by 15 minutes
      1.1497
      0.0497
      (4.52%)
      After Hours: 7:24PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      1.1497
      Bid
      1.10
      Ask
      1.19
      Volume
      288,146
      1.10 Day's Range 1.20
      0.99 52 Week Range 9.586
      Market Cap
      47.359M
      Previous Close
      1.14
      Open
      1.19
      Last Trade
      100
      @
      1.1497
      (formt)
      Last Trade Time
      Financial Volume
      $ 323,964
      VWAP
      1.1243
      Average Volume (3m)
      844,465
      Shares Outstanding
      41,542,744
      Dividend Yield
      -
      PE Ratio
      -0.53
      Earnings Per Share (EPS)
      -2.09
      Revenue
      14.92M
      Net Profit
      -86.88M

      About Carisma Therapeutics Inc

      Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company¿s lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company¿s second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.carismatx.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Carisma Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CARM. The last closing price for Carisma Therapeutics was $1.14. Over the last year, Carisma Therapeutics shares have traded in a share price range of $ 0.99 to $ 9.586.

      Carisma Therapeutics currently has 41,542,744 shares outstanding. The market capitalization of Carisma Therapeutics is $47.36 million. Carisma Therapeutics has a price to earnings ratio (PE ratio) of -0.53.

      CARM Latest News

      More News

      Form 8-K - Current report

      July 09 2024
      Edgar (US Regulatory)

      Carmila: Resources Devoted to the Liquidity Contract as of 30 June 2024

      Regulatory News: At 30 June 2024, resources made available for the liquidity agreement concluded by Carmila (Paris:CA) with Kepler Cheuvreux were the following: - 80,485 CARMILA shares; - Euro...

      July 05 2024
      Business Wire

      CARMILA: Information Concerning the Total Number of Voting Rights and Share

      provided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des marchés financiers (General regulation of...

      July 02 2024
      Business Wire

      Carmila: Closing of the Acquisition of Galimmo SCA

      Carmila announces the closing of the acquisition of 93% of the share capital of Galimmo SCA Galimmo’s portfolio of 52 assets, mainly located in the North-East of France, was valued at 675...

      July 01 2024
      Business Wire

      Carisma Therapeutics Announces Changes to its Board of Directors

      Carisma Therapeutics Announces Changes to its Board of Directors PR Newswire PHILADELPHIA, July 1, 2024 Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and...

      July 01 2024
      PR Newswire (US)

      Carmila : Participation dans Galimmo SCA potentiellement portée à 99,9%

      Regulatory News: Le 28 juin 2024, Carmila (Paris:CARM) a consenti à une entité gérée par Primonial REIM France une promesse unilatérale d’achat portant sur l’intégralité de la participation...

      July 01 2024
      Business Wire

      Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

      Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna PR Newswire PHILADELPHIA, June 27, 2024...

      June 27 2024
      PR Newswire (US)

      Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum

      Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum PR Newswire PHILADELPHIA, June 25, 2024 PHILADELPHIA, June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq:...

      June 25 2024
      PR Newswire (US)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.0503-4.191666666671.21.381.14143931.23908744CS
      40.139713.83168316831.011.9121823001.45032284CS
      12-0.5503-32.37058823531.71.90.998444651.43449812CS
      26-1.2303-51.69327731092.382.770.994729761.57633529CS
      52-8.1803-87.67738478039.339.5860.993414572.36872027CS
      156-4.6403-80.14335060455.799.76620.993232713.25434032CS
      260-4.6403-80.14335060455.799.76620.993232713.25434032CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      SERVServe Robotics Inc
      $ 7.51
      (185.55%)
      		262.73M
      AUGXAugmedix Inc
      $ 2.27
      (147.71%)
      		21.87M
      XCURExicure Inc
      $ 0.5351
      (76.02%)
      		14.02M
      PSNLPersonalis Inc
      $ 3.83
      (56.33%)
      		22.76M
      MDBHMDB Capital Holdings LLC
      $ 10.675
      (37.21%)
      		126.13k
      SPWRSunPower Corporation
      $ 0.6735
      (-55.40%)
      		124.61M
      HYZNHyzon Motors Inc
      $ 0.149
      (-47.54%)
      		23.63M
      MEDSTRxADE Health Inc
      $ 14.92
      (-33.45%)
      		223.27k
      SILOSilo Pharma Inc
      $ 2.50
      (-27.95%)
      		11.93M
      KITTNauticus Robotics Inc
      $ 0.0935
      (-27.46%)
      		28.43M
      SERVServe Robotics Inc
      $ 7.51
      (185.55%)
      		262.73M
      NVDANVIDIA Corporation
      $ 117.93
      (-2.61%)
      		206.41M
      SXTP60 Degrees Pharmaceuticals Inc
      $ 0.2602
      (5.77%)
      		202.14M
      SQQQProShares UltraPro Short QQQ
      $ 8.46
      (2.79%)
      		184.21M
      SPWRSunPower Corporation
      $ 0.6735
      (-55.40%)
      		119.98M

      CARM Discussion

      View Posts
      PonkenPlonken PonkenPlonken 3 weeks ago
      pretty strong
      nice tech$
      👍️0
      glenn1919 glenn1919 3 weeks ago
      CARM.......................https://stockcharts.com/h-sc/ui?s=CARM&p=W&b=5&g=0&id=p86431144783
      👍️0
      Awl416 Awl416 3 weeks ago
      Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
      👍️0
      Termite7 Termite7 2 months ago
      Could it be CARM under $0.30 ....???.......Thanks!!!
      👍️0
      axelvento axelvento 2 months ago
      $1.46 bouncer
      👍️0
      PonkenPlonken PonkenPlonken 3 months ago
      https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-023-00537-x
      MRNA provides the tech, 3bln + in biobucks and has not so distant private relative with TOP tier c suite.
      👍️0
      Monksdream Monksdream 4 months ago
      CARM under $3
      👍️0
      mrplmer mrplmer 7 months ago
      Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
      👍️0
      mrplmer mrplmer 7 months ago
      Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
      👍️0
      81vette 81vette 7 months ago
      1st higher high today and bid growing now,I got some 2.64,will see if dump continues or not
      👍️0
      81vette 81vette 7 months ago
      Yea,distribution only so far today,I am watching for accumulation to start after this dumpathon,short interest went up 300% today also, 100k now,no sign of institutional buying yet,they currently hold 19%
      👍️0
      stock1ace1 stock1ace1 7 months ago
      Red on news .. we no what that means lol
      👍️0
      81vette 81vette 7 months ago
      Deal with Moderna for cancer cures,institutional might buy now lol,went up last time on this news,analysts target $9.50,short 2.45M,not optionable is good,gap filled down now,52 week low 2 weeks ago
      👍️0

      Your Recent History

      NASDAQ
      CARM
      Carisma Therapeutics
      Delayed Upgrade Clock